Trials / Completed
CompletedNCT01106742
Agaricus Blazei Murill (ABM) in Patients With Inflammatory Bowel Disease (IBD)
Potential Anti-inflammatory Effect of Mushroom Extract From Agaricus Blazei Murill (ABM) in Patients With Inflammatory Bowel Disease (IBD)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Ullevaal University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Based on the anti-inflammatory and stabilising effect of the AbM, (Agaricus Blazei Murill) based mushroom extract AndoSanTM on cytokine release in blood in vivo and ex vivo in healthy volunteers after 12 days consumption, the aim in this study is to investigate whether same effect is valid in patients with IBD (inflammatory bowel disease). In addition, calprotectin an abundant cytosolic protein in neutrophils and a surrogate marker for degree of intestinal inflammation will be measured in blood and feces of these patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | AndoSan | AndoSan, 20mlx3, 12 days |
Timeline
- Start date
- 2009-03-01
- Primary completion
- 2011-07-01
- Completion
- 2011-07-01
- First posted
- 2010-04-20
- Last updated
- 2011-07-19
Locations
1 site across 1 country: Norway
Source: ClinicalTrials.gov record NCT01106742. Inclusion in this directory is not an endorsement.